The present invention provides a percutaneously absorbable preparation comprising 2-[(1-benzylpiperidin-4-yl) methyl]-5,6-dimethoxyindan-1-one and/or a hydrochloride thereof wherein the percuneously absorbable preoaration is able to administer to a patient such that Cmax per unit surface area of the percutaneously absorbable preparation is 0.025 to 0.5 ng/ml·cm 2 in a plasma concentration profile.